Tag: oral proteins and peptides market share

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Oral Proteins And Peptides Market Size Forecast: How Big Could The Market Get By 2030?

The oral proteins and peptides market size has seen significant expansion in recent years. This market is projected to increase from $1.56 billion in 2025 to $1.91 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 22.5%. The historical growth experienced by this market can be attributed to factors such as limited oral bioavailability of proteins and peptides, reliance on injectable formulations, growing prevalence of diabetes and gastrointestinal disorders, increasing research in peptide therapeutics, and regulatory approvals for early oral peptide drugs.

The oral proteins and peptides market is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $4.26 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 22.2%. This growth over the forecast period is fueled by the advancement of innovative delivery technologies for oral proteins, the expansion of chronic disease management initiatives, the increasing embrace of personalized and combination therapies, higher healthcare spending on metabolic and hormonal disorders, and the integration of digital tools for adherence and monitoring. Significant trends for this period encompass the rising adoption of oral insulin and other therapeutic peptides, the evolution of personalized medicine and targeted oral protein treatments, an increased focus on therapies for gastrointestinal disorders, the broader availability of oral protein formulations for diabetes and metabolic conditions, and innovations in long-acting and combination oral protein products.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=44278343&type=smp&name=Oral%20Proteins%20And%20Peptides%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Oral Proteins And Peptides Market Growth Catalysts And Demand Drivers

The expansion of the biopharmaceutical sector is projected to drive the future development of the oral proteins and peptides market. This industry segment, part of the wider pharmaceutical field, is dedicated to the creation, manufacture, and sale of medications originating from biological sources. This sector’s expansion stems from progress in biotechnology, a rising need for personalized treatments, a greater incidence of chronic illnesses, and increased spending on research and development initiatives. Within biopharmaceuticals, oral proteins and peptides present an opportunity for administering therapies without invasion, thereby improving patient adherence and lessening the requirement for injections. They are capable of targeting particular ailments, exhibiting better stability and uptake within the digestive system. As an illustration, in October 2025, data from the Bioscience and Health Technology Sector, a source of UK government statistics, indicated that during 2023/2024, the UK life sciences industry contained 6,170 businesses spanning 7,320 companies. These operations provided employment for 359,600 individuals and achieved a turnover of £146.9 ($169.69) billion. Consequently, the expanding biopharmaceutical industry is serving as a catalyst for the growth of the oral proteins and peptides market.

Oral Proteins And Peptides Market Breakdown By Product Type And Application

The oral proteins and peptides market covered in this report is segmented –

1) By Drug Type: Linaclotide, Calcitonin, Insulin, Plecanatide, Octreotide

2) By Biological Target: Guanylate Cyclase-C (GC-C), Insulin Receptor, Other Biological Targets

3) By Mechanism Of Action: Receptor Stimulation, Substrate Degradation, Other Mechanisms Of Action

4) By Application: Gastrointestinal Disorders, Bone Disease, Neurological Disorders, Diabetes, Metabolic Disorders, Hormonal Disorder, Cancer

Subsegments:

1) By Linaclotide: Indications For Irritable Bowel Syndrome (IBS), Indications For Chronic Idiopathic Constipation (CIC)

2) By Calcitonin: Calcitonin-Salmon, Synthetic Calcitonin, Calcitonin for Osteoporosis Treatment

3) By Insulin: Long-Acting Insulin, Combination Insulin Products, Oral Insulin Formulations

4) By Plecanatide: Indications For Chronic Idiopathic Constipation (CIC), Indications For Irritable Bowel Syndrome With Constipation (IBS-C)

5) By Octreotide: Long-Acting Octreotide Formulations, Short-Acting Octreotide Formulations, Indications For Acromegaly And Neuroendocrine Tumors

Oral Proteins And Peptides Market Trends Shaping Long-Term Demand

Major companies operating in the oral proteins and peptides market are focusing on developing innovative formulation technologies to enhance peptide stability, permeability, and bioavailability in oral dosage forms. These advancements aim to overcome traditional challenges such as enzymatic degradation and poor absorption in the gastrointestinal tract. For instance, in August 2025, BioMed X, a Germany-based biomedical research institute, launched a new collaboration with Novo Nordisk, a Denmark-based pharmaceutical company, to accelerate the development of next-generation oral peptide delivery technologies. The partnership will explore novel molecular strategies and delivery mechanisms to enable safe, effective, and patient-friendly oral peptide therapeutics. By integrating BioMed X’s early-stage research capabilities with Novo Nordisk’s expertise in peptide-based medicines, the collaboration aims to advance breakthrough oral drug delivery solutions and expand the therapeutic potential of peptide medicines across metabolic and chronic diseases.

Oral Proteins And Peptides Market Company Landscape And Competitive Strategy

Major companies operating in the oral proteins and peptides market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.

View The Full Oral Proteins And Peptides Market Report:

https://thebusinessresearchcompany.com/report/oral-proteins-and-peptides-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Oral Proteins And Peptides Market Global Footprint: Which Region Leads The Industry?

North America was the largest region in the oral proteins and peptides market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Oral Proteins And Peptides Market Revenue Growth Supported By A CAGR Of 4.26% Through 2030

Over the recent period, the market for oral proteins and peptides has experienced rapid expansion. Projected to rise from $1.56 billion in 2025 to $1.91 billion in 2026, it is expected to achieve a compound annual growth rate (CAGR) of 22.5%. This historical growth has been driven by factors such as the restricted oral bioavailability of proteins and peptides, a heavy dependence on injectable delivery methods, an increasing incidence of diabetes and gastrointestinal conditions, heightened research efforts in peptide therapeutics, and the granting of regulatory approvals for early-stage oral peptide medications.

The oral proteins and peptides market is anticipated to experience substantial expansion in the coming years. By 2030, it is projected to reach a value of $4.26 billion, reflecting a compound annual growth rate (CAGR) of 22.2%. This forecasted growth is driven by the creation of innovative delivery technologies for oral proteins, the broadening of chronic disease management initiatives, a growing preference for personalized and combination therapies, increased healthcare spending on metabolic and hormonal conditions, and the incorporation of digital adherence and monitoring systems. Key developments during this period are likely to feature the widespread use of oral insulin and other therapeutic peptides, progress in personalized medicine with targeted oral protein treatments, a heightened emphasis on therapies for gastrointestinal disorders, the broadening of oral protein solutions for diabetes and metabolic diseases, and improvements in long-lasting and combination oral protein products.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19629&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Oral Proteins And Peptides Market Growth Drivers: What Factors Are Accelerating Expansion?

The expansion of the biopharmaceutical sector is anticipated to drive forward the oral proteins and peptides market. This sector, a subset of the wider pharmaceutical industry, is dedicated to creating, manufacturing, and marketing drugs sourced from biological materials. Its growth is fueled by innovations in biotechnology, a heightened demand for tailored medical treatments, a rising incidence of chronic illnesses, and increased funding for research and development. Oral proteins and peptides within biopharmaceuticals present a means for non-invasive drug delivery, boosting patient adherence and minimizing the reliance on injections. These compounds can address particular diseases, offering improved stability and absorption within the gastrointestinal tract. To illustrate, according to the Bioscience and Health Technology Sector, a UK governmental statistics body, in October 2025, the UK life sciences field contained 6,170 businesses out of 7,320 companies during 2023/2024. These enterprises employed 359,600 individuals and produced a turnover of £146.9 billion ($169.69 billion). Consequently, the flourishing biopharmaceutical industry is propelling the oral proteins and peptides market forward.

Oral Proteins And Peptides Market Segment Landscape And Growth Potential

The oral proteins and peptides market covered in this report is segmented –

1) By Drug Type: Linaclotide, Calcitonin, Insulin, Plecanatide, Octreotide

2) By Biological Target: Guanylate Cyclase-C (GC-C), Insulin Receptor, Other Biological Targets

3) By Mechanism Of Action: Receptor Stimulation, Substrate Degradation, Other Mechanisms Of Action

4) By Application: Gastrointestinal Disorders, Bone Disease, Neurological Disorders, Diabetes, Metabolic Disorders, Hormonal Disorder, Cancer

Subsegments:

1) By Linaclotide: Indications For Irritable Bowel Syndrome (IBS), Indications For Chronic Idiopathic Constipation (CIC)

2) By Calcitonin: Calcitonin-Salmon, Synthetic Calcitonin, Calcitonin for Osteoporosis Treatment

3) By Insulin: Long-Acting Insulin, Combination Insulin Products, Oral Insulin Formulations

4) By Plecanatide: Indications For Chronic Idiopathic Constipation (CIC), Indications For Irritable Bowel Syndrome With Constipation (IBS-C)

5) By Octreotide: Long-Acting Octreotide Formulations, Short-Acting Octreotide Formulations, Indications For Acromegaly And Neuroendocrine Tumors

Oral Proteins And Peptides Market Trends: What Is Shaping Future Industry Growth?

Leading enterprises in the oral proteins and peptides market are prioritizing the creation of novel formulation technologies aimed at boosting peptide stability, permeability, and bioavailability within oral dosage forms. These efforts strive to overcome persistent obstacles like enzymatic breakdown and insufficient absorption in the gastrointestinal tract. As an example, in August 2025, BioMed X, a biomedical research institute headquartered in Germany, initiated a new partnership with Novo Nordisk, a pharmaceutical company based in Denmark, designed to expedite progress in next-generation oral peptide delivery technologies. Through this collaboration, fresh molecular strategies and delivery mechanisms are being investigated to facilitate the development of safe, effective, and patient-friendly oral peptide therapeutics. By merging BioMed X’s early-stage research strengths with Novo Nordisk’s proficiency in peptide-based drugs, this alliance seeks to propel groundbreaking oral drug delivery methods forward and broaden the application of peptide therapies for metabolic and chronic conditions.

Oral Proteins And Peptides Market Competitive Landscape: Who Are The Leading Companies?

Major companies operating in the oral proteins and peptides market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.

Access The Complete Oral Proteins And Peptides Market Report:

https://www.thebusinessresearchcompany.com/report/oral-proteins-and-peptides-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Oral Proteins And Peptides Market Regional Outlook: Where Are The Largest Opportunities Located?

North America was the largest region in the oral proteins and peptides market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The Oral Proteins And Peptides Market’s Market Value Anticipated To Evolve From 2026 To 2030?

The size of the oral proteins and peptides market has experienced substantial expansion in recent years. This market is projected to expand from $1.56 billion in 2025 to $1.91 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 22.5%. Historically, this growth has been driven by factors such as the limited oral bioavailability of proteins and peptides, a reliance on injectable formulations, the rising occurrence of diabetes and gastrointestinal disorders, increasing research efforts in peptide therapeutics, and the regulatory approvals for early oral peptide drugs.

The oral proteins and peptides market is anticipated to experience substantial growth in the coming years. It is projected to achieve a market size of $4.26 billion in 2030, expanding at a compound annual growth rate (CAGR) of 22.2%. This expected growth during the forecast period can be attributed to the development of new delivery technologies for oral proteins, the expansion of programs for managing chronic diseases, the increasing acceptance of personalized and combination therapies, a rise in healthcare spending on metabolic and hormonal disorders, and the integration of digital tools for adherence and monitoring. Significant trends for this period include the growing adoption of oral insulin and other therapeutic peptides, the advancement of personalized medicine and targeted oral protein therapies, a heightened focus on treatments for gastrointestinal disorders, the broadening of oral protein formulations for diabetes and metabolic disorders, and progress in long-acting and combination oral protein products.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19629&type=smp

Which Major Factors Are Contributing To The Development Of The Oral Proteins And Peptides Market?

The expansion of the biopharmaceutical industry is anticipated to boost the development of the oral proteins and peptides market moving ahead. This sector, part of the wider pharmaceutical industry, concentrates on the creation, manufacturing, and marketing of medications originating from biological sources. Its expansion can be attributed to progress in biotechnology, an increasing need for personalized medicine, a higher incidence of chronic illnesses, and greater funding for research and development efforts. Within biopharmaceuticals, oral proteins and peptides present opportunities for drug delivery without invasive procedures, improving patient adherence and decreasing the reliance on injections. These substances are capable of targeting particular diseases, demonstrating enhanced stability and absorption within the digestive system. As an illustration, in October 2025, data from the Bioscience and Health Technology Sector, a source of UK government statistics, indicated that during 2023/2024, the UK life sciences industry contained 6,170 businesses operating within 7,320 companies. These entities provided employment for 359,600 individuals and achieved a turnover of £146.9 ($169.69) billion. Consequently, the expanding biopharmaceutical industry is a significant impetus behind the growth of the oral proteins and peptides market.

What Are The Core Segment Classifications In The Oral Proteins And Peptides Market?

The oral proteins and peptides market covered in this report is segmented –

1) By Drug Type: Linaclotide, Calcitonin, Insulin, Plecanatide, Octreotide

2) By Biological Target: Guanylate Cyclase-C (GC-C), Insulin Receptor, Other Biological Targets

3) By Mechanism Of Action: Receptor Stimulation, Substrate Degradation, Other Mechanisms Of Action

4) By Application: Gastrointestinal Disorders, Bone Disease, Neurological Disorders, Diabetes, Metabolic Disorders, Hormonal Disorder, Cancer

Subsegments:

1) By Linaclotide: Indications For Irritable Bowel Syndrome (IBS), Indications For Chronic Idiopathic Constipation (CIC)

2) By Calcitonin: Calcitonin-Salmon, Synthetic Calcitonin, Calcitonin for Osteoporosis Treatment

3) By Insulin: Long-Acting Insulin, Combination Insulin Products, Oral Insulin Formulations

4) By Plecanatide: Indications For Chronic Idiopathic Constipation (CIC), Indications For Irritable Bowel Syndrome With Constipation (IBS-C)

5) By Octreotide: Long-Acting Octreotide Formulations, Short-Acting Octreotide Formulations, Indications For Acromegaly And Neuroendocrine Tumors

Which Trends Are Guiding The Development Of The Oral Proteins And Peptides Market?

Leading firms within the oral proteins and peptides market are dedicating efforts to devising novel formulation technologies designed to improve the stability, permeability, and bioavailability of peptides when administered orally. Such innovations seek to address long-standing hurdles, including enzymatic breakdown and insufficient absorption within the gastrointestinal system. A notable example occurred in August 2025, when BioMed X, a biomedical research institute based in Germany, initiated a fresh collaborative effort with Novo Nordisk, a pharmaceutical company located in Denmark. This partnership aims to expedite the creation of advanced oral peptide delivery technologies. This collaboration intends to investigate innovative molecular approaches and administration methods to facilitate the production of oral peptide therapeutics that are safe, efficacious, and convenient for patients. Through combining BioMed X’s competencies in early-stage research with Novo Nordisk’s profound knowledge in peptide-derived medicines, the joint venture seeks to propel cutting-edge oral drug delivery solutions forward and broaden the therapeutic scope of peptide medicines across various metabolic and chronic conditions.

Who Are The Major Companies Operating In The Oral Proteins And Peptides Market?

Major companies operating in the oral proteins and peptides market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.

Access The Complete Oral Proteins And Peptides Market Report:

https://www.thebusinessresearchcompany.com/report/oral-proteins-and-peptides-global-market-report

Which Region Leads The Oral Proteins And Peptides Market By Size?

North America was the largest region in the oral proteins and peptides market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Oral Proteins And Peptides Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=19629&type=smp

Browse Through More Reports Similar to the Global Oral Proteins And Peptides Market 2026, By The Business Research Company

Oral Biologics And Biosimilar Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

Oral Contraceptive Pills Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-contraceptive-pills-global-market-report

Oral Thin Films Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-thin-films-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Oral Proteins And Peptides Market Expected To Reach Based On Its 2026 Value?

The oral proteins and peptides market size has witnessed significant expansion in recent years. It is anticipated to grow from $1.56 billion in 2025 to $1.91 billion in 2026, achieving a compound annual growth rate (CAGR) of 22.5%. The historical growth of this market can be attributed to factors such as the limited oral bioavailability of proteins and peptides, the reliance on injectable formulations, the increasing prevalence of diabetes and gastrointestinal disorders, expanding research into peptide therapeutics, and regulatory approvals for early oral peptide drugs.

The oral proteins and peptides market is projected to experience rapid expansion over the coming years. This market is anticipated to reach $4.26 billion by 2030, driven by a compound annual growth rate (CAGR) of 22.2%. Several factors will contribute to this growth during the forecast period, including the creation of new oral protein delivery methods, the enlargement of chronic disease management initiatives, a growing preference for personalized and combination treatments, increased spending on healthcare for metabolic and hormonal conditions, and the incorporation of digital tools for adherence and monitoring. Key trends anticipated during this period encompass the increasing use of oral insulin and other therapeutic peptides, the expansion of personalized medicine alongside targeted oral protein treatments, a heightened emphasis on therapies for gastrointestinal disorders, the broadening range of oral protein formulations designed for diabetes and metabolic disorders, and innovations in long-acting and combination oral protein products.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19629&type=smp

What Significant Factors Are Influencing The Oral Proteins And Peptides Market Expansion?

The expansion of the biopharmaceutical sector is anticipated to fuel the future development of the oral proteins and peptides market. This industry operates as a segment of the wider pharmaceutical domain, concentrating on the creation, manufacturing, and marketing of medications sourced from biological entities. Its expansion is attributable to breakthroughs in biotechnology, the escalating need for tailored medical treatments, a greater incidence of long-term illnesses, and increased funding for research and development initiatives. Within biopharmaceuticals, oral proteins and peptides present a promising avenue for administering treatments without invasive procedures, thereby improving patient adherence and decreasing reliance on injections. These compounds can target particular ailments, offering better stability and absorption once they enter the digestive system. As an illustration, data from October 2025 by the Bioscience and Health Technology Sector, a UK government statistical source, indicated that during 2023/2024, the UK life sciences industry comprised 6,170 businesses functioning across 7,320 distinct companies. These entities collectively employed 359,600 individuals and achieved a turnover of £146.9 ($169.69) billion. Consequently, the expanding biopharmaceutical sector is a key catalyst for the advancement of the oral proteins and peptides market.

How Is The Oral Proteins And Peptides Market Organized By Segment Classification?

The oral proteins and peptides market covered in this report is segmented –

1) By Drug Type: Linaclotide, Calcitonin, Insulin, Plecanatide, Octreotide

2) By Biological Target: Guanylate Cyclase-C (GC-C), Insulin Receptor, Other Biological Targets

3) By Mechanism Of Action: Receptor Stimulation, Substrate Degradation, Other Mechanisms Of Action

4) By Application: Gastrointestinal Disorders, Bone Disease, Neurological Disorders, Diabetes, Metabolic Disorders, Hormonal Disorder, Cancer

Subsegments:

1) By Linaclotide: Indications For Irritable Bowel Syndrome (IBS), Indications For Chronic Idiopathic Constipation (CIC)

2) By Calcitonin: Calcitonin-Salmon, Synthetic Calcitonin, Calcitonin for Osteoporosis Treatment

3) By Insulin: Long-Acting Insulin, Combination Insulin Products, Oral Insulin Formulations

4) By Plecanatide: Indications For Chronic Idiopathic Constipation (CIC), Indications For Irritable Bowel Syndrome With Constipation (IBS-C)

5) By Octreotide: Long-Acting Octreotide Formulations, Short-Acting Octreotide Formulations, Indications For Acromegaly And Neuroendocrine Tumors

What Trends Are Affecting The Growth Of The Oral Proteins And Peptides Market?

Leading companies active in the oral proteins and peptides market are prioritizing the development of innovative formulation technologies to enhance peptide stability, permeability, and bioavailability within oral dosage forms. These advancements are designed to address traditional hurdles like enzymatic degradation and poor absorption within the gastrointestinal tract. For example, in August 2025, BioMed X, a Germany-based biomedical research institute, initiated a new collaboration with Novo Nordisk, a Denmark-based pharmaceutical company, to accelerate the progress of next-generation oral peptide delivery technologies. This partnership intends to explore novel molecular strategies and delivery mechanisms to enable the creation of safe, effective, and patient-friendly oral peptide therapeutics. By integrating BioMed X’s early-stage research capabilities with Novo Nordisk’s expertise in peptide-based medicines, the collaboration aims to advance breakthrough oral drug delivery solutions and expand the therapeutic potential of peptide medicines across metabolic and chronic diseases.

Who Are The Industry Participants Involved In The Oral Proteins And Peptides Market?

Major companies operating in the oral proteins and peptides market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.

Get The Full Oral Proteins And Peptides Market Report:

https://www.thebusinessresearchcompany.com/report/oral-proteins-and-peptides-global-market-report

Which Geographic Region Dominates The Oral Proteins And Peptides Market?

North America was the largest region in the oral proteins and peptides market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Oral Proteins And Peptides Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/oral-proteins-and-peptides-global-market-report

Browse Through More Reports Similar to the Global Oral Proteins And Peptides Market 2026, By The Business Research Company

Oral Biologics And Biosimilar Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

Oral Contraceptive Pills Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-contraceptive-pills-global-market-report

Oral Thin Films Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-thin-films-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Oral Proteins And Peptides Market From 2026 To 2030?

The oral proteins and peptides market has experienced rapid expansion over recent years. This market is projected to expand from $1.56 billion in 2025 to $1.91 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 22.5%. Historically, this expansion has been driven by several factors, including the challenge of limited oral bioavailability of proteins and peptides, a historical reliance on injectable formulations, the rising prevalence of diabetes and gastrointestinal disorders, advancements in research concerning peptide therapeutics, and the granting of regulatory approvals for early oral peptide drugs.

The market for oral proteins and peptides is projected to experience rapid expansion over the coming years. This market is forecast to reach a valuation of $4.26 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 22.2%. Several factors are driving this growth during the projection period, including the introduction of innovative oral protein delivery technologies, the broadening scope of chronic disease management initiatives, the increasing uptake of tailored and multi-drug treatments, higher healthcare spending directed at metabolic and hormonal conditions, and the incorporation of digital tools for patient adherence and monitoring. Key trends anticipated for this period encompass the growing use of oral insulin and various therapeutic peptides, the expansion of personalized medicine and targeted oral protein interventions, an intensified focus on therapies for gastrointestinal disorders, the wider availability of oral protein formulations addressing diabetes and metabolic conditions, and innovations in long-acting and combination oral protein products.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19629&type=smp

What Key Drivers Are Influencing The Growth Of The Oral Proteins And Peptides Market?

The expansion of the biopharmaceutical sector is projected to fuel the advancement of the oral proteins and peptides market in the future. This industry is a specialized segment within the wider pharmaceutical domain, dedicated to the creation, manufacture, and commercialization of medications sourced from biological entities. The increase in the biopharmaceutical industry’s scale is attributed to breakthroughs in biotechnology, a rising need for individualized medical treatments, the increasing commonness of chronic illnesses, and heightened investment in research and development. Within biopharmaceuticals, oral proteins and peptides present an opportunity for administering therapies without invasive procedures, thereby improving patient adherence and lessening the necessity for injections. They are capable of targeting specific conditions, exhibiting improved stability and uptake within the gastrointestinal tract. As an illustration, figures from October 2025 by the UK’s Bioscience and Health Technology Sector indicate that during 2023/2024, the UK life sciences industry contained 6,170 businesses operating under 7,320 companies. These enterprises provided employment for 359,600 individuals and achieved a turnover of £146.9 ($169.69) billion. Consequently, the expanding biopharmaceutical industry is a key factor propelling the growth of the oral proteins and peptides market.

Which Segments Are Included In The Analysis Of The Oral Proteins And Peptides Market?

The oral proteins and peptides market covered in this report is segmented –

1) By Drug Type: Linaclotide, Calcitonin, Insulin, Plecanatide, Octreotide

2) By Biological Target: Guanylate Cyclase-C (GC-C), Insulin Receptor, Other Biological Targets

3) By Mechanism Of Action: Receptor Stimulation, Substrate Degradation, Other Mechanisms Of Action

4) By Application: Gastrointestinal Disorders, Bone Disease, Neurological Disorders, Diabetes, Metabolic Disorders, Hormonal Disorder, Cancer

Subsegments:

1) By Linaclotide: Indications For Irritable Bowel Syndrome (IBS), Indications For Chronic Idiopathic Constipation (CIC)

2) By Calcitonin: Calcitonin-Salmon, Synthetic Calcitonin, Calcitonin for Osteoporosis Treatment

3) By Insulin: Long-Acting Insulin, Combination Insulin Products, Oral Insulin Formulations

4) By Plecanatide: Indications For Chronic Idiopathic Constipation (CIC), Indications For Irritable Bowel Syndrome With Constipation (IBS-C)

5) By Octreotide: Long-Acting Octreotide Formulations, Short-Acting Octreotide Formulations, Indications For Acromegaly And Neuroendocrine Tumors

Which Trends Are Impacting The Growth Of The Oral Proteins And Peptides Market?

Major companies engaged in the oral proteins and peptides market are concentrating on innovating formulation technologies to improve peptide stability, absorption, and bioavailability in oral dosage forms. These advancements are designed to address traditional obstacles such as enzymatic degradation and poor absorption in the digestive system. For example, in August 2025, BioMed X, a biomedical research institute located in Germany, commenced a new collaboration with Novo Nordisk, a pharmaceutical company based in Denmark, to expedite the progress of next-generation oral peptide delivery technologies. This partnership intends to investigate new molecular strategies and delivery methods to enable the creation of safe, effective, and user-friendly oral peptide therapeutics. By merging BioMed X’s early-stage research capabilities with Novo Nordisk’s specialized knowledge in peptide-based medicines, the joint effort aims to further cutting-edge oral drug delivery solutions and broaden the therapeutic applicability of peptide medicines across metabolic and chronic illnesses.

Which Key Industry Participants Are Active In The Oral Proteins And Peptides Market?

Major companies operating in the oral proteins and peptides market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.

Read the full oral proteins and peptides market report here:

https://www.thebusinessresearchcompany.com/report/oral-proteins-and-peptides-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Oral Proteins And Peptides Market?

North America was the largest region in the oral proteins and peptides market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oral Proteins And Peptides Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19629&type=smp

Browse Through More Reports Similar to the Global Oral Proteins And Peptides Market 2026, By The Business Research Company

Oral Biologics And Biosimilar Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

Oral Contraceptive Pills Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-contraceptive-pills-global-market-report

Oral Thin Films Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-thin-films-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the oral proteins and peptides market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Oral Proteins And Peptides Market show for the 2026–2030 period?

The oral proteins and peptides market size has experienced significant expansion in recent years. It is projected to grow from $1.56 billion in 2025 to $1.91 billion in 2026, at a compound annual growth rate (CAGR) of 22.5%. The market’s historical growth can be attributed to several factors, including the limited oral bioavailability of proteins and peptides, a reliance on injectable formulations, the growing prevalence of diabetes and gastrointestinal disorders, increasing research in peptide therapeutics, and regulatory approvals for early oral peptide drugs.

The oral proteins and peptides market size is projected to undergo exponential growth in the coming years, with expectations to reach $4.26 billion by 2030, driven by a compound annual growth rate (CAGR) of 22.2%. This anticipated growth during the forecast period is largely due to the creation of novel delivery technologies for oral proteins, the expansion of chronic disease management programs, an increasing adoption of personalized and combination therapies, rising healthcare spending on metabolic and hormonal disorders, and the integration of digital tools for adherence and monitoring. Prominent trends observed in this period include the increasing uptake of oral insulin and other therapeutic peptides, advancements in personalized medicine and targeted oral protein therapies, a growing emphasis on treatments for gastrointestinal disorders, the expansion of oral protein formulations designed for diabetes and metabolic disorders, and progress in long-acting and combination oral protein products.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19629&type=smp

What Drivers Are Shaping The Development Of The Oral Proteins And Peptides Market?

The expanding biopharmaceutical industry is anticipated to fuel the progression of the oral proteins and peptides market moving forward. This sector, a component of the wider pharmaceutical industry, focuses on the development, production, and commercialization of medications sourced from biological origins. The biopharmaceutical industry’s expansion is attributed to advancements in biotechnology, a rising demand for personalized medicine, an increase in chronic disease prevalence, and greater investment in research and development. Oral proteins and peptides utilized in biopharmaceuticals present an avenue for non-invasive delivery of treatments, leading to enhanced patient compliance and a reduced need for injections. They are effective in targeting specific diseases, demonstrating improved stability and absorption within the digestive system. For instance, data from October 2025, provided by the UK-based government statistics body, the Bioscience and Health Technology Sector, revealed that in 2023/2024, the UK life sciences industry encompassed 6,170 businesses distributed among 7,320 companies. These businesses collectively employed 359,600 people and generated a turnover of £146.9 ($169.69) billion. Thus, the burgeoning biopharmaceutical industry is indeed a primary driver behind the growth of the oral proteins and peptides market.

Which Segments Are Contributing To The Growth Of The Oral Proteins And Peptides Market?

The oral proteins and peptides market covered in this report is segmented –

1) By Drug Type: Linaclotide, Calcitonin, Insulin, Plecanatide, Octreotide

2) By Biological Target: Guanylate Cyclase-C (GC-C), Insulin Receptor, Other Biological Targets

3) By Mechanism Of Action: Receptor Stimulation, Substrate Degradation, Other Mechanisms Of Action

4) By Application: Gastrointestinal Disorders, Bone Disease, Neurological Disorders, Diabetes, Metabolic Disorders, Hormonal Disorder, Cancer

Subsegments:

1) By Linaclotide: Indications For Irritable Bowel Syndrome (IBS), Indications For Chronic Idiopathic Constipation (CIC)

2) By Calcitonin: Calcitonin-Salmon, Synthetic Calcitonin, Calcitonin for Osteoporosis Treatment

3) By Insulin: Long-Acting Insulin, Combination Insulin Products, Oral Insulin Formulations

4) By Plecanatide: Indications For Chronic Idiopathic Constipation (CIC), Indications For Irritable Bowel Syndrome With Constipation (IBS-C)

5) By Octreotide: Long-Acting Octreotide Formulations, Short-Acting Octreotide Formulations, Indications For Acromegaly And Neuroendocrine Tumors

Which Trends Are Influencing The Performance And Direction Of The Oral Proteins And Peptides Market?

Leading entities within the oral proteins and peptides market are prioritizing the development of innovative formulation technologies to bolster peptide stability, permeability, and bioavailability in oral dosage forms. These enhancements are designed to address persistent issues like enzymatic degradation and inadequate absorption within the gastrointestinal tract. A notable example is the new collaboration launched in August 2025 between BioMed X, a Germany-based biomedical research institute, and Novo Nordisk, a Denmark-based pharmaceutical company, aimed at accelerating the advancement of next-generation oral peptide delivery technologies. This partnership intends to investigate novel molecular strategies and delivery mechanisms, facilitating the creation of oral peptide therapeutics that are safe, effective, and convenient for patients. By integrating BioMed X’s early-stage research capabilities with Novo Nordisk’s extensive experience in peptide-based medicines, the joint initiative strives to propel breakthrough oral drug delivery solutions forward and expand the therapeutic applicability of peptide medicines across various metabolic and chronic diseases.

Who Are The Major Companies Operating In The Oral Proteins And Peptides Market?

Major companies operating in the oral proteins and peptides market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/oral-proteins-and-peptides-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Oral Proteins And Peptides Market?

North America was the largest region in the oral proteins and peptides market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Oral Proteins And Peptides Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19629&type=smp

Browse Through More Reports Similar to the Global Oral Proteins And Peptides Market 2026, By The Business Research Company

Oral Biologics And Biosimilar Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

Oral Contraceptive Pills Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-contraceptive-pills-global-market-report

Oral Thin Films Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-thin-films-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the oral proteins and peptides market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Oral Proteins And Peptides Market show for the 2026–2030 period?

The oral proteins and peptides market size has experienced significant expansion in recent years. It is projected to grow from $1.56 billion in 2025 to $1.91 billion in 2026, at a compound annual growth rate (CAGR) of 22.5%. The market’s historical growth can be attributed to several factors, including the limited oral bioavailability of proteins and peptides, a reliance on injectable formulations, the growing prevalence of diabetes and gastrointestinal disorders, increasing research in peptide therapeutics, and regulatory approvals for early oral peptide drugs.

The oral proteins and peptides market size is projected to undergo exponential growth in the coming years, with expectations to reach $4.26 billion by 2030, driven by a compound annual growth rate (CAGR) of 22.2%. This anticipated growth during the forecast period is largely due to the creation of novel delivery technologies for oral proteins, the expansion of chronic disease management programs, an increasing adoption of personalized and combination therapies, rising healthcare spending on metabolic and hormonal disorders, and the integration of digital tools for adherence and monitoring. Prominent trends observed in this period include the increasing uptake of oral insulin and other therapeutic peptides, advancements in personalized medicine and targeted oral protein therapies, a growing emphasis on treatments for gastrointestinal disorders, the expansion of oral protein formulations designed for diabetes and metabolic disorders, and progress in long-acting and combination oral protein products.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19629&type=smp

What Drivers Are Shaping The Development Of The Oral Proteins And Peptides Market?

The expanding biopharmaceutical industry is anticipated to fuel the progression of the oral proteins and peptides market moving forward. This sector, a component of the wider pharmaceutical industry, focuses on the development, production, and commercialization of medications sourced from biological origins. The biopharmaceutical industry’s expansion is attributed to advancements in biotechnology, a rising demand for personalized medicine, an increase in chronic disease prevalence, and greater investment in research and development. Oral proteins and peptides utilized in biopharmaceuticals present an avenue for non-invasive delivery of treatments, leading to enhanced patient compliance and a reduced need for injections. They are effective in targeting specific diseases, demonstrating improved stability and absorption within the digestive system. For instance, data from October 2025, provided by the UK-based government statistics body, the Bioscience and Health Technology Sector, revealed that in 2023/2024, the UK life sciences industry encompassed 6,170 businesses distributed among 7,320 companies. These businesses collectively employed 359,600 people and generated a turnover of £146.9 ($169.69) billion. Thus, the burgeoning biopharmaceutical industry is indeed a primary driver behind the growth of the oral proteins and peptides market.

Which Segments Are Contributing To The Growth Of The Oral Proteins And Peptides Market?

The oral proteins and peptides market covered in this report is segmented –

1) By Drug Type: Linaclotide, Calcitonin, Insulin, Plecanatide, Octreotide

2) By Biological Target: Guanylate Cyclase-C (GC-C), Insulin Receptor, Other Biological Targets

3) By Mechanism Of Action: Receptor Stimulation, Substrate Degradation, Other Mechanisms Of Action

4) By Application: Gastrointestinal Disorders, Bone Disease, Neurological Disorders, Diabetes, Metabolic Disorders, Hormonal Disorder, Cancer

Subsegments:

1) By Linaclotide: Indications For Irritable Bowel Syndrome (IBS), Indications For Chronic Idiopathic Constipation (CIC)

2) By Calcitonin: Calcitonin-Salmon, Synthetic Calcitonin, Calcitonin for Osteoporosis Treatment

3) By Insulin: Long-Acting Insulin, Combination Insulin Products, Oral Insulin Formulations

4) By Plecanatide: Indications For Chronic Idiopathic Constipation (CIC), Indications For Irritable Bowel Syndrome With Constipation (IBS-C)

5) By Octreotide: Long-Acting Octreotide Formulations, Short-Acting Octreotide Formulations, Indications For Acromegaly And Neuroendocrine Tumors

Which Trends Are Influencing The Performance And Direction Of The Oral Proteins And Peptides Market?

Leading entities within the oral proteins and peptides market are prioritizing the development of innovative formulation technologies to bolster peptide stability, permeability, and bioavailability in oral dosage forms. These enhancements are designed to address persistent issues like enzymatic degradation and inadequate absorption within the gastrointestinal tract. A notable example is the new collaboration launched in August 2025 between BioMed X, a Germany-based biomedical research institute, and Novo Nordisk, a Denmark-based pharmaceutical company, aimed at accelerating the advancement of next-generation oral peptide delivery technologies. This partnership intends to investigate novel molecular strategies and delivery mechanisms, facilitating the creation of oral peptide therapeutics that are safe, effective, and convenient for patients. By integrating BioMed X’s early-stage research capabilities with Novo Nordisk’s extensive experience in peptide-based medicines, the joint initiative strives to propel breakthrough oral drug delivery solutions forward and expand the therapeutic applicability of peptide medicines across various metabolic and chronic diseases.

Who Are The Major Companies Operating In The Oral Proteins And Peptides Market?

Major companies operating in the oral proteins and peptides market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/oral-proteins-and-peptides-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Oral Proteins And Peptides Market?

North America was the largest region in the oral proteins and peptides market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Oral Proteins And Peptides Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19629&type=smp

Browse Through More Reports Similar to the Global Oral Proteins And Peptides Market 2026, By The Business Research Company

Oral Biologics And Biosimilar Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

Oral Contraceptive Pills Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-contraceptive-pills-global-market-report

Oral Thin Films Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-thin-films-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the oral proteins and peptides industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#How Has The Oral Proteins And Peptides Market Size Shifted, And What Is the Outlook Through 2034?#_x000D_

The market for oral proteins and peptides has seen tremendous growth in recent years, projected to rise from $1.27 billion in 2024, to $1.56 billion in 2025, marking a compound annual growth rate (CAGR) of 22.7%. This significant growth in the past can be credited to the increasing occurrence of chronic diseases, amplified investments in biotechnology for the creation of oral protein therapies, a heightened consumer preference for non-invasive treatments, the expansion of the biopharmaceutical industry, and an escalating focus on personalized medicine._x000D_

_x000D_

The market for oral proteins and peptides is predicted to undergo massive expansion in the coming years, expected to reach a valuation of $3.49 billion in 2029 with a CAGR of 22.3%. This projected expansion during the forecast period can be attributed to factors such as heightened focus on patient-oriented drugs, increasing presence of the elderly population, escalating healthcare spending, a growing demand for diagnostics in cancer, and a rising preference for orally administered medicine. Key trends during the forecast period are anticipated to include the creation of new, improved oral peptides boasting increased stability and effectiveness, the utilization of artificial intelligence in the drug discovery processes for oral prescriptions, the introduction of advanced medical treatments, progress in drug delivery technologies, and next-gen oral insulin formulations._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=19629&type=smp_x000D_

_x000D_

#Which Primay Drivers Are Accelerating Growth in the Oral Proteins And Peptides Market?#_x000D_

The expansion of the biopharmaceutical industry is predicted to stimulate the oral proteins and peptides market’s progression. The biopharmaceutical industry, a subsection of the larger pharmaceutical industry, specializes in creating, manufacturing, and marketing medicines sourced from biological materials. This industry’s expansion is powered by advancements in biotechnology, a rising demand for personalized medical treatment, an escalating prevalence of chronic illnesses, and increased investment in research and development. Oral proteins and peptides in biopharmaceuticals provide a promising option for non-invasive delivery methods, enhancing the willingness of patients to follow medical directives and decreasing the reliance on injections. These substances offer targeted disease treatment with improved stability and absorption in the gastrointestinal system. For instance, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a trade association based in Belgium representing the pharmaceutical industry, recorded a total biopharmaceutical production of $384,200 million (€340,000 million) in Europe in 2022, reflecting an upward shift of nearly 4.95% from $366,267 million (€323,950 million) in 2021. Consequently, the burgeoning biopharmaceutical industry propels the further growth of the oral proteins and peptides market._x000D_

_x000D_

#Which Primary Segments of the Oral Proteins And Peptides Market Are Driving Growth and Industry Transformations?#_x000D_

The oral proteins and peptidesmarket covered in this report is segmented –_x000D_

_x000D_

1) By Drug Type: Linaclotide, Calcitonin, Insulin, Plecanatide, Octreotide_x000D_

2) By Biological Target: Guanylate Cyclase-C (GC-C), Insulin Receptor, Oxalate, Other Biological Targets_x000D_

3) By Mechanism Of Action: Receptor Stimulation, Substrate Degradation, Other Mechanisms Of Action_x000D_

4) By Application: Gastrointestinal Disorders, Bone Disease, Neurological Disorders, Diabetes, Metabolic Disorders, Hormonal Disorder, Cancer_x000D_

_x000D_

Subsegments:_x000D_

1) By Linaclotide: Indications For Irritable Bowel Syndrome (IBS), Indications For Chronic Idiopathic Constipation (CIC)_x000D_

2) By Calcitonin: Calcitonin-Salmon, Synthetic Calcitonin, Calcitonin for Osteoporosis Treatment_x000D_

3) By Insulin: Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin Products, Oral Insulin Formulations_x000D_

4) By Plecanatide: Indications For Chronic Idiopathic Constipation (CIC), Indications For Irritable Bowel Syndrome With Constipation (IBS-C)_x000D_

5) By Octreotide: Long-Acting Octreotide Formulations, Short-Acting Octreotide Formulations, Indications For Acromegaly And Neuroendocrine Tumors_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=19629&type=smp_x000D_

_x000D_

#Which Regions Are Key Players in the Growth of the Oral Proteins And Peptides Market?#_x000D_

North America was the largest region in the oral proteins and peptides market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Are the Strategic Trends Steering the Oral Proteins And Peptides Market Direction?#_x000D_

Leading corporations in the oral proteins and peptides market are focusing on the creation of novel products, like Oral Semaglutide, to improve patient compliance and ease. Oral Semaglutide represents a major breakthrough in oral proteins and peptides. Traditionally given through injection to control type 2 diabetes, and more recently obesity, Semaglutide functions as a glucagon-like peptide-1 (GLP-1) receptor agonist. In January 2022, for instance, the first ever oral semaglutide was introduced by Novo Nordisk India, a health care company based in India, signifying a progressive stride in the treatment of diabetes. Semaglutide, a GLP-1 receptor analogue (GLP-1 RA), previously was only available as an injectable, and now providing a more convenient oral alternative for managing type 2 diabetes. This innovation doesn’t only revolutionise diabetes care but lays the foundation for future advancements in oral insulin formulations, possibly paving the way for more efficient and patient-oriented treatment alternatives._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/oral-proteins-and-peptides-global-market-report_x000D_

_x000D_

#What Parameters Are Used to Define the Oral Proteins And Peptides Market?#_x000D_

Oral Proteins and Peptides refer to therapeutic proteins and peptides administered orally, typically in pills, capsules, or other ingestible formats. These biologically active molecules are designed to treat various medical conditions by leveraging their specific actions within the body._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19629_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Are the Primary Drivers Supporting the Market Growth of theOral Proteins And Peptides Market?

The expanding biopharmaceutical industry is expected to drive the growth of the oral proteins and peptides market. The biopharmaceutical industry focuses on developing drugs from biological sources, with increasing demand for personalized medicine and advancements in biotechnology. Oral proteins and peptides offer an alternative to injections, improving patient compliance and targeting specific diseases. In June 2023, the European Federation of Pharmaceutical Industries and Associations reported a growth of about 4.95% in biopharmaceutical production in Europe. Therefore, the growth of the biopharmaceutical industry is propelling the oral proteins and peptides market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19629&type=smp

#What Long-Term Growth Rate is Expected for theOral Proteins And Peptides Market Between 2025 and 2034?

The oral proteins and peptides market size is projected to grow from $1.27 billion in 2024 to $1.56 billion in 2025 at a CAGR of 22.7%. The growth is attributed to the rising prevalence of chronic diseases, increasing investments in biotechnology for oral protein treatments, consumer preference for non-invasive treatments, the expanding biopharmaceutical industry, and a focus on personalized medicine.

The oral proteins and peptides market size is expected to grow to $3.49 billion in 2029 at a CAGR of 22.3%. Growth is driven by a focus on patient-centric drugs, aging populations, rising healthcare expenditures, cancer diagnostics, and preference for oral drugs. Key trends include the development of novel oral peptides, AI integration in drug discovery, advanced drug delivery technologies, and oral insulin formulations.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19629

What Are the Latest Innovations Influencing theOral Proteins And Peptides Market?

Companies in the oral proteins and peptides market are focusing on developing innovative products like Oral Semaglutide to improve patient comfort and adherence. Oral semaglutide, a novel medication for treating type 2 diabetes and obesity, was launched in January 2022 by Novo Nordisk India. Unlike the injectable version, this oral form of semaglutide offers more convenience for patients, marking a significant breakthrough in diabetes treatment and paving the way for potential oral insulin formulations in the future.

Who Are the Major Industry Players Accelerating Growth in theOral Proteins And Peptides Market?

Major companies operating in the oral proteins and peptides market are Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/oral-proteins-and-peptides-global-market-report

Which Primary Segments of the Oral Proteins And Peptides Market Are Driving Growth and Industry Transformations?

The oral proteins and peptidesmarket covered in this report is segmented –

1) By Drug Type: Linaclotide, Calcitonin, Insulin, Plecanatide, Octreotide

2) By Biological Target: Guanylate Cyclase-C (GC-C), Insulin Receptor, Oxalate, Other Biological Targets

3) By Mechanism Of Action: Receptor Stimulation, Substrate Degradation, Other Mechanisms Of Action

4) By Application: Gastrointestinal Disorders, Bone Disease, Neurological Disorders, Diabetes, Metabolic Disorders, Hormonal Disorder, Cancer

Subsegments:

1) By Linaclotide: Indications For Irritable Bowel Syndrome (IBS), Indications For Chronic Idiopathic Constipation (CIC)

2) By Calcitonin: Calcitonin-Salmon, Synthetic Calcitonin, Calcitonin for Osteoporosis Treatment

3) By Insulin: Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin Products, Oral Insulin Formulations

4) By Plecanatide: Indications For Chronic Idiopathic Constipation (CIC), Indications For Irritable Bowel Syndrome With Constipation (IBS-C)

5) By Octreotide: Long-Acting Octreotide Formulations, Short-Acting Octreotide Formulations, Indications For Acromegaly And Neuroendocrine Tumors

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=19629&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of theOral Proteins And Peptides Market?# Market?

North America was the largest region in the oral proteins and peptides market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Oral Proteins And Peptides Market 2025, By The Business Research Company:

Behavioral and Mental Health Software Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/behavioral-and-mental-health-software-global-market-report

Oral Biologics & Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report

Intraoral Cameras Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/intraoral-cameras-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: